A double-blind, placebo-controlled trial assessing the efficacy of varenicline tartrate for alcohol dependence

Journal of Addiction Medicine

Volumn 7, Issue 4, 2013, Pages 277-286

  Litten, Raye Z ^a   Ryan, Megan L ^a   Fertig, Joanne B ^a   Falk, Daniel E ^a   Johnson, Bankole ^b   Dunn, Kelly E ^c   Green, Alan I ^d   Pettinati, Helen M ^e   Ciraulo, Domenic A ^f   Sarid Segal, Ofra ^f   Kampman, Kyle ^e   Brunette, Mary F ^d   Strain, Eric C ^c   Tiouririne, Nassima A ^b   Ransom, Janet ^g   Scott, Charles ^g   Stout, Robert ^h  

^a NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d DARTMOUTH MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g Fast Track Drugs and Biologics   (United States)

^h Pacific Institute for Research and Evaluation   (United States)

Author keywords

Alcohol dependence; Alcohol use disorder; Champix; Chantix; Randomized placebo controlled clinical trial; Varenicline

Indexed keywords

PLACEBO; VARENICLINE;

ABNORMAL DREAMING; ADULT; ALCOHOL ABSTINENCE; ALCOHOL CONSUMPTION; ALCOHOL WITHDRAWAL; ALCOHOLISM; ARTICLE; CLINICAL EFFECTIVENESS; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRINKING BEHAVIOR; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SMOKING; SYNDROME DELINEATION;

ADULT; ALCOHOLISM; BENZAZEPINES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; QUINOXALINES; TREATMENT OUTCOME;

EID: 84881256735     PISSN: 19320620     EISSN: 19353227     Source Type: Journal    
DOI: 10.1097/ADM.0b013e31829623f4     Document Type: Article

References (49)

1. Blomqvist O, Henandez-Avila CA, Van Kirk J, et al. Mecamylamine modifies the pharmacokinetics and reinforcing effects of alcohol. Alcohol Clin Exp Res 2002;26:326-331.
2. Bouchery EE, Henrick MS, Harwood J, et al. Economic costs of excessive alcohol consumption in the U. S., 2006. Am J Prev Med 2011;41:516-524.
3. Cohen J. A power primer. Psychol Bull 1992;112:155-159.
4. Davis TJ, De Fiebre CM. Alcohol's actions on neuronal nicotinic acetylcholine receptors. Alcohol Res Health 2006;29:179-185.
5. Ericson M, Lof E, Stromberg R, et al. The smoking cessation medication varenicline attenuates alcohol and nicotine inteactionsinthe rat mesolimbic dopamine system. J Pharm Exp Ther 2009;32:225-230.
6. Farook JM, Lewis B, Gaddis JG, et al. Effects of mecamylamine on alcohol consumption and preference in male C57BL/6J mice. Pharmacology 2009;83:379-384.
7. Feduccia AA, Chatterjee S, Bartlett S. Neuronal nicotinic acetylcholine receptors: neuroplastic changes underlying alcohol and nicotine addictions. Front Mol Neurosci 2012;5:1-18.
8. Feinn R, Kranzler HR. Does effect size in naltrexone trials for alcohol dependence differ for single-site vs. multi-center studies? Alcohol Clin Exp Res 2005;29:983-988.
9. Flannery B, Volpicelli J, Pettinati H. Psychometric properties of the Penn Alcohol Craving Scale. Alcohol Clin Exp Res 1999;23:1289-1295.
10. Fucito LM, Toll BA, Wu R, et al. A preliminary investigation of varenicline for heavy drinking smokers. Psychopharmacology 2011;215:655-663.
11. Gonzales D, Rennard S, Nides M, et al. Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation. JAMA 2006;296:47-55.
12. Grady SR, Drenan RM, Breining SR, et al. Structural differences determine the relative selectivity of nicotinic compounds for native α4β2, α6β2, α3β4, and α7-nicotine acetylcholine receptors. Neuropharmacology 2010;58:1054-1066.
13. Grant BF, Dawson DA, Stinson FS, et al. The 12 month prevalence and trends in DSM-IV alcohol abuse and dependence: United States, 1991-1992 and 2001-2002. Drug Alcohol Depend 2004;74:223-234.
14. Grucza R, Bierut L. Co-occurring risk factors for alcohol dependence and habitual smoking. Alcohol Res Health 2006;29:172-178.
15. Heatherton TF, Kozlowski LT, Frecker RC, et al. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict 1991;86:1119-1127.
16. Hurley L, Taylor R, Tizabi Y. Positive and negative effects of alcohol and nicotine and their interactions: a mechanistic review. Neurotox Res 2012;21:57-69.
17. Le AD, Corrigall WA, Harding JW, et al. Involvement of nicotinic receptors in alcohol self-administration. Alcohol Clin Exp Res 2000;24:155-163.
18. Lim SS, Vos T, Flaxman AD, et al. Lancet 2012;380:2224-2260.
19. Litten RZ, Egli M, Heilig M, et al. Medications development to treat alcohol dependence: a vision for the next decade. Addict Biol 2012;17:513-527.
20. Maisel NC, Blodgett JC, Wilbourne PL, et al. Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful? Addiction 2013;108:275-293.
21. Mason BJ, Lehert P. Acamprosate for alcohol dependence: a sex-specific meta-analysis based on individual patient data. Alcohol Clin Exp Res 2012;36:497-508.
22. McKee SA, Harrison E L R, O'Malley SS, et al. Varenicline reduces alcohol self-administration in heavy-drinking smokers. Biol Psychiatry 2009;66:185-195.
23. McKee SA, O'Malley SS, Shi J, et al. Effect of transdermal nicotine replacement on alcohol responses and alcohol self-administration. Psychopharmacology 2008;196:189-200.
24. Mihalak KB, Carroll FI, Luetje CW. Varenicline is a partial agonist at a4ß2 and a full agonist at α7 neuronal nicotinic receptors. Mol Pharmacol 2006;70:801-805.
25. Miller W. The Drinker Inventory of Consequences (DrInC): an instrument for assessing adverse consequences of alcohol abuse. In: Mattson M, Marshall LA, eds. NIAAA Project MATCH Monograph Series. Vol 4. Bethesda, MD: National Institute on Alcohol Abuse and Alcoholism, 1995:1-94.
26. Miller W. Form 90: A Structured Assessment Interview for Drinking and Related Behaviors (Test Manual). Bethesda, MD: National Institute on Alcohol Abuse and Alcoholism, 1996. NIH publication no. 96-4004.
27. Mitchell JM, Teague CH, Kayser AS, et al. Varenicline decreases alcohol consumption in heavy-drinking smokers. Psychopharmacology 2012;223:299-306.
28. National Institute on Alcohol Abuse and Alcoholism (NIAAA). Helping Patients Who Drink Too Much: A Clinician's Guide. Bethesda, MD: National Institutes of Health, 2005. NIH publication no. 07-3769.
29. National Institute on Alcohol Abuse and Alcoholism (NIAAA). Rethinking Drinking. Bethesda, MD: National Institutes of Health, 2009. NIH publication no. 09-3770.
30. O'Brien C. Addiction and dependence in DSM-V. Addiction 2010;106:866-867.
31. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962;10:790-812.
32. Peduzzi P, Concato J, Kemper E, et al. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol 1996;49:1373-1379.
33. Pfizer, Chantix (varenicline). Package Insert. New York, NY: Pfizer, 2009.
34. Posner K, Brent D, Lucas C, et al. Columbia-Suicide Severity Rating Scale (C-SSRS) [Columbia University Web site]. Version January 14, 2009. Available at: http://cssrs.columbia.edu/docs/C-SSRS-1-14-09-Since-Last-Visit-Clinical.pdf. Accessed January 15, 2012.
35. Ray LA, Miranda R, Kahler CW, et al. Pharmacological effects of naltrexone and intravenous alcohol on craving for cigarettes among light smokers: a pilot study. Psychopharmacology 2007;193:449-456.
36. Rehm J, Baliunas D, Borges G L G, et al. The relation between different dimensions of alcohol consumption and burden of disease: an overview. Addiction 2010;105:817-843.
37. Rehm J, Mathers C, Popova S, et al. Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. Lancet 2009;373:2223-2233.
38. Rehm J, Zatonksi W, Taylor B, et al. Epidemiology and alcohol policy in Europe. Addiction 2011;106(suppl 1):11-19.
39. Sajja RK, Rahman S. Lobeline and cytisine reduce voluntary ethanol drinking behavior in male C57BL/6J mice. Prog Neuro-Psychopharmacol Biol Psychiatry 2011;35:257-264.
40. Schalaepfer I, Hoft N, Ehringer M. The genetic components of alcohol and nicotine co-addiction: from genes to behavior. Curr Drug Abuse Rev 2008;1:2:124-134
41. SDI, Vector One. National (VONA) and Total Patient Tracker (TPT). May 2006-July 2011. Data extracted September 2011.
42. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M. I. N. I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59(suppl 20):22-33; quiz 34-57.
43. Sobell L, Sobell M. Timeline follow-back: a technique for assessing self-reported alcohol consumption. In: Litten R, Allen J, eds. Measuring Alcohol Consumption: Psychosocial and Biochemical Methods. Totowa, NJ: Humana Press, 1992:41-72.
44. Steensland P, Simms JA, Holgate J, et al. Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking. Proc Natl Acad Sci 2007;104:12518-12523.
45. Szabo S. The World Health Organization Quality of Life (WHO-QOL). In: Spiker B, ed. Quality of Life and Pharmacoeconomics in Clinical Trials. Philadelphia, PA: Lippincott-Raven Publishers, 1996;355-362
46. Tizabi Y, Copeland R, Louis VA, et al. Effects of combined systemic alcohol and central nicotine administration into ventral tegmental area on dopamine release in the nucleus accumbens. Alcohol Clin Exp Res 2002;26:394-399.
47. Werner M, Rentz A, Frank L, et al. Participant consequence measures. Paper presented at: The Annual Meeting of the Research Society on Alcoholism; June 2008; Washington, DC.
48. Willenbring ML, Huang SW, Gardner MB. Helping patients who drink too much: an evidence-based guide for primary care physicians. Am Fam Physicians 2009;80:1-7.
49. Wouda JA, Riga D, De Vries W, et al. Varenicline attenuates cue-induced relapse to alcohol, but not nicotine seeking, while reducing inhibitory response control. Psychopharmacology 2011;216:267-277.